Apligraf® is a living cell-based product, developed by Organogenesis and indicated for the treatment of venous leg ulcers and diabetic foot ulcers.
- the first bio-engineered cell based product to receive FDA approval (in 1998).
- the only commercially available bi-layered bio-engineered cell based product.
- the only product approved by the FDA to treat both diabetic foot ulcers and venous leg ulcers
The two layers of Apligraf® make it effective in speeding up wound healing and achieving healing in wounds previously unresponsive to treatment.
For more information on Apligraf® please visit www.apligraf.com.
For Apligraf regulatory documentation, please visit